 What efforts go behind the scene till a new drug hits the market? Do patients benefit? Are they cured? How do we control health care costs? What are the new drugs in the making? To know more, visit http://www.drugsinthemaking.com Dr.Shruti Bhat, an Expert in Pharmaceutical industry, brings to you some highlights from current pharma and clinical research news, views and data.
Heartburn Drug Renamed To Avoid Medicinal Mix-Ups. Press reports that, Takeda Pharmaceuticals will change the name of a heartburn drug that has repeatedly been confused by pharmacists with drugs meant to treat cancer and other ailments." ...Cabazitaxel May Improve Metastatic Prostate Cancer Survival. According to a study presented at the Genitourinary Cancers Symposium, "cosponsored by the American Society for Clinical Oncology (ASCO), the American Society for Radiation Oncology, and the Society of Urologic Oncology," the Sanofi-Aventis prostate cancer drug cabazitaxel "increased survival by 30%... Hydroxychloroquine May Help Delay Skin Damage In SLE Patients. According to a study published in March issue of Arthritis Care & Research, "treatment with hydroxychloroquine (Plaquenil) may help delay the occurrence of skin damage in patients with systemic lupus erythematosus (SLE)." ...FDA Approves Pre-Filled Injection Pens Of Somatropin. The FDA approved pre-filled injection pens of the endogenous growth hormone disorder drug somatropin (Norditropin) for adult and youth patients." The Norditropin FlexPro "produces an audible click that tells patients the medication has been dispensed...FDA Approves Weekly Immune-Replacement Therapy. CSL Ltd., the world's second-biggest maker of treatments derived from blood, won US clearance to sell Hizentra (IgPro20)...Details of above topics/ data at http://www.pharm-education.com/2010/03/cabazitaxel-may-improve-metastatic.htmlDisclaimer- The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.Http://www.drshrutibhat.comExpert at leading Pharmaceutical R&D.
Translates innovative concepts to PROFITS.
Do you have questions for the author?
Here are some updates on drug research and technology from my reading-Internet usage to research drug information doubles amongst people in north America -Since 2005, the number of patients using the Internet to research prescription drug information has doubled to 102.3 million, according to a new study from Manhattan Research. In addition, health-related social media, in particular, has flourished in recent years with the increased popularity of online patient communities, social networking and health 2.0 applications.
Depomed Inc claims its extended-release form of gabapentin reduced post-shingles pain-Depomed, Inc. Allegedly reported a successful late stage clinical trial of DM-1796, which is a drug intended to treat pain following the viral infection shingles. The company said that DM-1796 significantly reduced post-shingles pain compared to placebo after 10 weeks of treatment, and it plans to file for Food and Drug Administration approval by the end of March 2010. DM-1796 is an extended-release form of gabapentin, which is used to treat pain disorders and epilepsy.
Number of doctors using e-prescriptions will rise to more than double in 2010-The number of physicians using electronic prescribing will have more than doubled in 2010,according to the e-prescribing network Surescripts. The company said more than 140,000 - 23 % of all office-based physicians, nurse practitioners and physician assistants in the United States are E-prescribing today. EU approves sale of saxagliptin for diabetics-Bristol-Myers Squibb Co. Press release stated that its new diabetes drug, Onglyza [saxagliptin], has been approved for sale in the European Union's 27 countries. Onglyza is expected to go on sale in the EU in this quarter, and was approved to be sold to improve blood sugar levels in combination with metformin, sulphonylurea or thiazolidinedione, when those drugs alone do not adequately control glycemic levels. For further details on this topic, please visit- http://www.pharm-education.com/2009/11/drug-research-and-technology-update_15.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading- Besides showing positive signs for good skin health and weight loss trigger...Resveratrol may lower blood sugar levels in mice, researchers say-According to a study published online in the Journal of Endocrinology by researchers at University of Texas, medical center, "resveratrol...was found to lower blood sugar levels and improve insulin levels when injected directly into the brains of mice fed very high-calorie diets. Quality and Safety
Adverse drug events jumped in 2008, according to USFDA data statistics -USFDA received 25 percent more reports of adverse drug events in 2008 compared with 2007, according to a new QuarterWatch report from the Institute for Safe Medication Practices. In 2008, the FDA received reports of nearly 100,800 cases of serious injury related to drug use...compared with 80,600 in 2007, the largest over a one-year period since the FDA began collecting data in 1998. Researcher says lidocaine patch as effective as pregabalin in relieving diabetics' neuropathic pain-A dermal patch containing 5% lidocaine (Lidoderm) proved as effective as pregabalin (Lyrica) in relieving neuropathic pain in diabetic patients with dramatically fewer side effects, according to a researcher at the European Association for the Study of Diabetes meeting. For details, please visit, http://www.pharm-education.com/2009/11/drug-research-and-technology-update_14.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading- Window for administering medications to limit damage from stroke may be wider !Medications to limit damage from a stroke by dissolving blood clots must be given within three hours of the event, according to standard guidelines. However, a research paper from The Lancet Neurology indicates that, this window of opportunity may extend to 4.5hours.
USFDA extends indication for Colchicine -USFDA has extended the indication for the gout treatment and mediterranean fever drug Colchicine (Colcrys) to include prevention of acute gout flares. Researchers say aldosterone antagonists only prescribed to one-third of heart failure patients-Journal of the American Medical Association., reports that "most hospitalized heart failure patients are sent home without widely recommended inexpensive pills, despite a program to get more doctors to follow treatment guidelines. For further reading on this topic, please visit-http://www.pharm-education.com/2009/11/drug-research-and-technology-update_13.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading- FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric UseThe USFDA has reportedly approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus. Further information is available at-http://www.drugs.com/newdrugs/fda-approves-seasonal-influenza-vaccine-fluarix-pediatric-use-1695.html
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney.
FDA approves expanded indication for Micardis.The USFDA has expanded the indication for the antihypertension drug telmisartan (Micardis), making it the first angiotensin receptor blocker approved for primary prevention in high-risk patients unable to take an ACE inhibitor. The FDA also granted new approval for Twynsta, a drug product containing telmisartan and amlodipine in combination.For further reading on this topic, please visit-http://www.pharm-education.com/2009/11/drug-research-and-technology-update_12.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading-
Studies happening on drug based on a snake venom for potential heart failure treatment !
The Wall Street Journal reported, researchers believed that a drug, currently known as CD-NP, based on venom from the Eastern Green Mamba snake may be used to help very ill patients with heart failure. Early research on the drug indicated that it increased kidney function but did not greatly reduce blood pressure.
Study suggests acetaminophen makes vaccines less potent :
A study report sponsored by GlaxoSmithKline and published in The Lancet states "studies done in the Czech Republic, found that acetaminophen makes some vaccines less potent." CDC researchers said in an editorial that the "study offered 'a compelling case' against routine dosing but that the issue required more study.
European regulators grant orphan drug status to hepatocellular carcinoma treatment-
A leading Canadian medical journal published that, "Jennerex Inc.'s lead cancer drug called JX-594, could enjoy market exclusivity in Europe for a decade after a regulatory agency granted the company's product “orphan” drug status.
FDA rejects Rituxan for patients with earlier stages of Rheumatoid Arthritis-
The USFDA has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan [rituximab] for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
For further reading on these topics please visit-
http://www.pharm-education.com/2009/11/drug-research-and-technology-update_11.html
Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading- Nicotine vaccines- do experiments show failure to meet primary endpoint? The Times "Booster Shots" blog reported that a company working on an "anti-smoking vaccine" similar to the much anticipated product undergoing testing by Nabi Pharmaceuticals "has not been so successful."
Studies see increased skin cancer risk in patients taking anti-TNF drugs.Medical conference reports at the the American College of Rheumatology, stated that, "Rheumatoid arthritis patients treated with potent tumor necrosis factor inhibitors ran an increased risk of developing skin cancer."
FDA strengthens warning for Dexferrum.USFDA website reported that, "The FDA has strengthened the black box warning for injectable iron dextran (Dexferrum), cautioning physicians to try a test dose first, due to a risk of anaphalactic reactions and even death." The altered warning "cautions that fatal reactions have occurred even after the test dose was tolerated." Three-day antibiotic course may be sufficient for pediatric tonsillectomy patients -According to a scientific publication reported in the Archives of Otolaryngology-Head & Neck Surgery, three days of antibiotics after a tonsillectomy will put kids back on a normal diet and activity level. Several studies have demonstrated that postoperative antibiotics reduce pain, thought to be caused when normal oral bacteria colonize the tonsillar fossae and cause inflammation. For indepth reading on this topic, please visit- http://www.pharm-education.com/2009/11/drug-research-and-technology-highlights.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Highlights on drug research and technology from my reading-
Stedesa may help lower seizure frequency in patients with epilepsy :Proceeding published from American Neurological Association reported, "Eslicarbazepine acetate (Stedesa), a European anti-epileptic drug not yet licensed in the US, reduced seizure frequency and was well tolerated as an add-on treatment in patients with refractory partial-onset seizures in a trial reported". Nortriptyline may be associated with increase in suicidal thoughts in men ?There are press reports that state "the largest clinical trial to date comparing" nortriptyline, "an older, tricyclic antidepressant, with" escitalopram, "a newer antidepressant of the selective serotonin reuptake inhibitor (SSRI) class, find that the emergence of suicidal thinking was almost 10 times more common in men taking the older" medicine "than in those taking the newer medication."
Infliximab may be associated with lower colectomy rates in UC patients.According to a research paper published in J.Gastroenterology, "Infliximab treatment is linked to lower colectomy rates in patients with moderate to severe active ulcerative colitis”. Cystic Fibrosis patients appear to be taking wide variety of medication ?Cystic fibrosis, a killer disease, like drowning on the inside ! Lead author Dr. Frank J. Accurso from University of Colorado researchers has found that "patients with cystic fibrosis are taking a wide variety of medication." For details on this topic please visit- http://www.pharm-education.com/2009/11/drug-research-and-technology-update_09.htmlDisclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some updates on drug research and technology from my reading-Folate-blocking drugs can increase birth defects if taken in first trimester:.The British Journal of Clinical Pharmacology researchers report a study that use of the folate-blocking drugs more than doubled the risk of congenital malformations of the fetus, including neural tube, cardiovascular and urinary tract defects. The drugs also "increased the risk of spina bifida and malformations of the brain more than sixfold.
Harvard researchers call for five years of market exclusivity for brand-name biologics.An online publication from Harvard Medical school reported, Congress should limit the proposed period of market exclusivity for brand-name biologics to five years, rather than the 12 years pending legislation,
FDA cracking down on flu treatment scams.The US FDA published that it is cracking down on hundreds of products being peddled as swine flu treatments. In a season of high anxiety, the Food and Drug Administration says online scam artists are doing big business in counterfeit flu drugs.
E-prescribing impacts compliance ? an investigational study.According to Healthcare IT digital new publication, "CVS Caremark and researchers from Harvard and Brigham and Women's Hospital are launching a study to investigate patient adherence to prescription drug therapies," and one of "the four key components of the study will look at how electronic prescribing impacts compliance.For in depth information on the above, please visit- http://www.pharm-education.com/2009/11/drug-research-and-technology-update.html Disclaimer : The above information has been cited from literature in public domain. This is for research purpose/ dissemination of knowledge only and should not be construed as medical advise.
Here are some drug research updates from my reading-
Trichostatin A may prevent premature labor.Trichostatin A, a cancer treatment, "may prevent premature labour," according to researchers from Newcastle University publication. Study indicates basal insulin regimen may be better for some patients with type 2 diabetes.A publication online in the New England Journal of Medicine indicates that "patients with type 2 diabetes who require insulin on top of oral therapy to control glycated hemoglobin may do better if they start on a basal insulin versus biphasic insulin or prandial insulin."
Researchers examine use of resveratrol to affect type 2 diabetes?According to a study published online in Journal Endocrinology, reports are that a study in mice population suggests that resveratrol "may help the body fend off type 2 diabetes". Is Liraglutide a better tool for weight loss than other obesity drugs ?In a study published online in The Lancet, it has been published that "In the fight against obesity, the investigational diabetes drug liraglutide (Victoza) may be a better tool than some weight loss drugs, even for patients who don't have diabetes, researchers said". Do incidences of roravirus infection potentially seem to decrease with vaccinations ? According to data published in the CDC's Morbidity and Mortality Weekly Report ,"Since routine vaccination of infants against rotavirus started in the United States in 2006, there's been a substantial reduction in the number of cases of rotavirus disease in children. For detailed reading on this topic please visit http://www.pharm-education.com/2009/11/drug-research-and-technology-updates.html
Disclaimer : The above information is for dissemination of knowledge only and should not be construed as medical advise. The scientific data presented here has been studied from leading publications already in public domain. The author however, assumes no responsibility regarding trueness of the data. Reference to stated journals and websites is encouraged in case of additional interest.
|
